Skip to main content
. 2017 Nov 29;7:16585. doi: 10.1038/s41598-017-16828-x

Table 1.

Neutralizing antibody titers and cross-reactivity in MS patients treated with IFNβ.

Neutralizing antibody Patients with cross-reactivity Patients without cross-reactivity
Low (≤100 TRU/ml) 63 (28.4%) 42 (66.7%) 21 (33.3%)
Intermediate (>100 and ≤300 TRU/ml) 27 (12.2%) 27 (100%)
High (>300 TRU/mL) 132 (59.4%) 131 (99.2%) 1 (0.8%)